![1]()
News
Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit
May 18, 2021
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close.
![1]()
News
PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
May 15, 2021
When treating patients with no history of heart failure within days of an acute myocardial infarction, sacubitril/valsartan showed safety but no clear superiority to ramipril.
News
Nutritional support may be lifesaving in heart failure
May 6, 2021
Patients with high-risk chronic heart failure given individualized nutritional support in-hospital had lower mortality following discharge, a new analysis shows.
![1]()
News
Torsemide over furosemide as first-line loop diuretic for HF
May 5, 2021
One “Thing We Do for No Reason” is use furosemide rather than torsemide as loop diuretic for patients with heart failure, said Dr. Anthony Breu.
![1]()
News
Higher MI shock survival with NCSI protocol: Final results
April 30, 2021
Final results of the National Cardiogenic Shock Initiative show better survival rates in acute MI shock than seen in previous North American studies, but 1-year mortality remains a problem.
News
No link seen between heart inflammation and COVID shots, CDC says
April 29, 2021
“We have not seen a signal and we’ve actually looked intentionally for the signal in the over 200 million doses we’ve given,” says CDC director Rochelle Walensky.
![1]()
News
Pneumonia risk soars in heart failure patients, especially HFpEF
April 19, 2021
An analysis of two large trials found that patients with heart failure have an elevated risk of pneumonia and related adverse cardiovascular events.
![1]()
News
Inpatient sodium imbalances linked to adverse COVID-19 outcomes
March 11, 2021
Hypernatremia during hospitalization was associated with increased COVID-19 mortality and to a greater need for ventilatory support.
![1]()
News
Heart failure redefined with new classifications, staging
March 8, 2021
Heart failure terminology gets a landmark reno, with a new universal definition, revised stages of development and progression, and updated LVEF classifications.
![1]()
News
More from DAPA-HF: Dapagliflozin quickly reduces heart failure events
February 22, 2021
Secondary analysis of DAPA-HF showed dapagliflozin significantly cut CV deaths or worsening heart failure within 28 days on treatment.
